Two MS medications for children with relapsing remitting MS (RRMS) will be amended on the Pharmaceutical Benefits Scheme (PBS), from 1 November 2019.
Approved by the Federal Health Minister, the Hon Greg Hunt MP, the two medications affected by the change are Gilenya® (fingolimod) and Tysabri® (natalizumab).
Decisions about treatments, taking into consideration the potential benefits and side effects for an individual’s circumstance, should be made in careful consultation with their healthcare team.
If you are unsure if Gilenya® or Tysabri® is the right treatment for you or your child, please consult with your neurologist.
For more information please head to MS Australia’s website.